Assessment of Serum Level of Lipocalin-2 In Patients with Alopecia Areata

Authors

• Mohammed S. Sultan, Department of Dermatology, Andrology & STDs, Faculty of Medicine, Mansoura University, Mansoura, Egypt
• N. M. Darwish, Department of Dermatology, Andrology & STDs, Faculty of Medicine, Mansoura University, Mansoura, Egypt
• Hosam Abdel Tawab, Department of Clinical Pathology (Clinical Immunology), Faculty of Medicine, Mansoura University, Mansoura, Egypt
• Asmaa M. Shalaby, Department of Dermatology, Talkha central Hospital, Faculty of Medicine, Mansoura University, Mansoura, EgyptFollow

Subject Area

Dermatology

Article Type

Original Study

Abstract

Background: Alopecia areata (AA) is a chronic autoimmune disease (AID)-causing non-scarring hair loss (NSHL), mainly on the scalp. It affects about 2% of people worldwide, usually starting in the third or fourth decade. This study aimed to evaluate serum lipocalin-2 levels in AA patients compared to healthy controls (HC), and to examine their correlation with disease severity Methods: This one-year prospective case-control study included 40 AA patients from Mansoura University Hospitals and 40 age- and sex-matched healthy control. Diagnosis was based on typical, well-defined non-inflammatory scalp hair loss (HL) confirmed by dermoscopy. Controls were healthy, with no autoimmune history or interfering medications. Patients were divided into two equal groups: (AA group): patients diagnosed with AA which subdivided into two subgroups according to severity according to SALT score: (Group A): >50% severity and (Group B)

Recommended Citation

Sultan, Mohammed S.; Darwish, N. M.; Tawab, Hosam Abdel; and Shalaby, Asmaa M. (2026) "Assessment of Serum Level of Lipocalin-2 In Patients with Alopecia Areata," Mansoura Medical Journal: Vol. 56 : Iss. 1 , Article 15.
Available at: https://doi.org/10.58775/2735-3990.1509

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.